Compare KYN & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | TWST |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | N/A | 2018 |
| Metric | KYN | TWST |
|---|---|---|
| Price | $12.38 | $31.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.88 |
| AVG Volume (30 Days) | 561.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-02-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | N/A | $15.10 |
| P/E Ratio | $13.79 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $7.84 | $23.30 |
| 52 Week High | $9.88 | $55.33 |
| Indicator | KYN | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 48.89 |
| Support Level | $12.01 | $30.21 |
| Resistance Level | $12.23 | $35.39 |
| Average True Range (ATR) | 0.19 | 1.60 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 98.87 | 26.93 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.